iShares Self-Driving EV and Tech vs Novartis AG — how do they compare? iShares Self-Driving EV and Tech trades at $33.48 (market cap $264.50M), while Novartis AG trades at $143.81 (market cap $268.57B). The key difference: Novartis AG is far larger — about 1015.4× iShares Self-Driving EV and Tech's market cap, and Novartis AG pays a 3.31% dividend while iShares Self-Driving EV and Tech pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and Novartis AG for 82 Days on average.
| IDRV | NVS | |
|---|---|---|
Market Cap | $264.50M | $268.57B |
Volume | 48,021 | 1,532,573 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $168.62 |
52-Week Low | $32.68 | $121.80 |
Typical Hold Time | 73 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →